Ultralife Q4 revenue rises on battery sales, faces $12.2 mln impairment

Ultralife

10/03/2026 11:09

Overview

Battery solutions provider's Q4 revenue rose 10.6% yr/yr

Company recorded $12.2 mln intangible asset impairment charge

Adjusted EBITDA for Q4 improved to $5.7 mln

Outlook

Ultralife expects sustainable profitable growth and incremental cash flow in 2026

Company aims to capitalize on increasing demand and multi-year program opportunities

Ultralife enters 2026 with strong backlog of $110 million

Result Drivers

BATTERY & ENERGY PRODUCTS GROWTH - Segment sales increased 15.1%, driven by 39.6% rise in medical battery sales and 20.4% increase in industrial market sales

INTANGIBLE ASSET IMPAIRMENT - $12.2 mln charge due to rebranding initiative consolidating sub-brands under Ultralife

BACKLOG INCREASE - Strong order flow increased backlog to $110.2 mln, up 22% from Q3

Company press release: ID:nGNX7bnzSR

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
$48.48 mln
Q4 EPS
-$0.45
Q4 Net Income
-$7.45 mln
Q4 Adjusted EBITDA
$5.70 mln
Q4 Operating Expenses
$22.66 mln
Q4 Operating Income
-$10.61 mln
Q4 Pretax Profit
-$10.21 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)